Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Could Alzheimer’s treatment drugs be the next big investor opportunity after obesity pills?
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...
earth1d
Human brains hold dormant viruses that come to life if you hit your head
The study reveals a potential link between concussions and the activation of dormant viruses, which may lead to ...
Alzheimer’s disease market expected to reach $19.3bn across the 8MM by 2033
While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...
Common injury may trigger Alzheimer’s disease by awakening hidden virus, study warns
Inflammation in the brain can reawaken dormant viruses, which may lead to the onset of neurodegenerative disease, a new study finds. New research has shown for the first time that repeated head ...
Breakthrough as scientists believe anti ageing vaccine ‘closer than ever’
Imagine a world where the mind remains sharp, even as the years pass by. Scientists are on the brink of a breakthrough that ...
Johnson & Johnson Gets FDA Fast-Track Designation for Posdinemab in Alzheimer's
The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...
Head injuries may reactivate herpes virus in brain, raise Alzheimer's risk: Study
A recent study by Tufts and Oxford universities reveals that head trauma can activate dormant herpes viruses in the brain, ...
Viruses living your brain may 'wake up' to cause dementia, say experts
Studies have long warned that blows to the head may raise the risk of neurodegenerative conditions. Now, scientists believe ...
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer’s Agitation “CALMA” and Expands Recruitment Strategy
POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...
The Victoria Advocate2d
Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow ...
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report
Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to ...